All > Friedreichs Ataxia

CTI-160l for Friedreich Ataxia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Friedreich AtaxiaCTI-1601 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).

Eligible Conditions
  • Friedreich Ataxia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
BIIB132
1
DT-216
1
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Through study completion, an average of 86 days

Day 29
Area under the concentration time curve (AUC) of CTI-1601 from time 0 through the last measurable time point
Cells
Maximum observed plasma concentration (Cmax) of CTI-1601 after multiple doses
Time to last observed plasma concentration (tlast) of CTI-1601 after multiple doses
Plasma
Day 58
Changes from baseline in frataxin levels in buccal cells
Day 86
Therapeutic procedure

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
BIIB132
1
DT-216
1
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN

Trial Design

2 Treatment Groups

CTI-160l
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

15 Total Participants · 2 Treatment Groups

Primary Treatment: CTI-160l · Has Placebo Group · Phase 2

CTI-160l
Biological
Experimental Group · 1 Intervention: CTI-1601 · Intervention Types: Biological
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CTI-1601
2020
Completed Phase 1
~60

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 86 days

Who is running the clinical trial?

Larimar Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
135 Total Patients Enrolled
4 Trials studying Friedreich Ataxia
135 Patients Enrolled for Friedreich Ataxia
Magdy Shenouda, M.D.Principal InvestigatorClinilabs, Inc.
2 Previous Clinical Trials
87 Total Patients Enrolled
2 Trials studying Friedreich Ataxia
87 Patients Enrolled for Friedreich Ataxia

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a genetically confirmed diagnosis of Friedreich's ataxia.
You are biologically male or female, 18 years of age or older.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top